Pex6 Gene Peroxisome Biogenesis Factor 6 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PEX6 encodes an AAA ATPase that forms a complex with PEX1 and is essential for peroxisome biogenesis [1].
PEX6 is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of PEX6 is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
| Property |
Value |
| Gene Symbol |
PEX6 |
| Full Name |
Peroxisome Biogenesis Factor 6 |
| Chromosomal Location |
6p21.1 |
| NCBI Gene ID |
5836 |
| Ensembl ID |
ENSG00000124587 |
| UniProt ID |
Q9Y5X3 |
- Encoded Protein: Pex6p
- Molecular Weight: ~104 kDa
- Subcellular Localization: Peroxisomal matrix
PEX6 is an AAA ATPase that forms a heterodimeric complex with PEX1. Together, they are involved in the ATP-dependent recycling of the peroxisomal targeting receptor PEX5 from the peroxisome membrane back to the cytosol [2].
The PEX1-PEX6 complex uses ATP hydrolysis to generate mechanical force for:
- Unfolding PEX5
- Translocation across the peroxisomal membrane
- Release of PEX5 into the cytosol for recycling
PEX6 mutations cause [3]:
- Zellweger syndrome
- Heimde syndrome
- Rhizomelic chondrodysplasia punctata type 4 (RCDP4)
PEX6 deficiency leads to:
- Severe peroxisomal dysfunction
- Neurological impairment
- Developmental delay
High expression in:
- Liver
- Kidney
- Brain (neurons and astrocytes)
The study of Pex6 Gene Peroxisome Biogenesis Factor 6 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
PEX6 dysfunction may contribute to AD pathogenesis:
- Peroxisomal dysfunction observed in AD brain tissue
- Reduced PEX6 expression correlates with disease severity
- Lipid metabolism alterations in peroxisomes affect amyloid processing
- PEX6 deficiency leads to increased oxidative stress
PEX6 and peroxisomal function in PD:
- PEX6 mutations identified in some PD patients
- Peroxisomal abnormalities in PD substantia nigra
- PEX6 deficiency affects mitochondrial quality control
- Link between peroxisomal and mitochondrial dysfunction
PEX6 maintains peroxisome-ER interactions:
- PEX6 localizes to peroxisome-ER membrane contacts
- Dysfunction disrupts lipid metabolism
- ER stress response activated
- Implications for neurodegenerative processes
Peroxisomes metabolize very long-chain fatty acids (VLCFAs):
- PEX6 deficiency accumulates VLCFAs
- VLCFA accumulation is neurotoxic
- Elevated VLCFAs found in AD and PD brain
- Therapeutic targeting of VLCFA metabolism
¶ PEX6 Structure and Mechanism
¶ AAA+ ATPase Domain
PEX6 contains conserved AAA+ motifs:
- Walker A (P-loop) for ATP binding
- Walker B for ATP hydrolysis
- Sensor domains for nucleotide sensing
- Arginine finger for ATPase activity
PEX6 forms hexameric rings:
- Stack of two AAA+ rings
- Central pore for substrate translocation
- ATP-dependent conformational changes
- Mechanical unfolding activity
Key PEX6 interactions:
- PEX1: AAA+ partner for complex formation
- PEX5: Peroxisomal targeting receptor (substrate)
- PEX15: Peroxisomal membrane anchor
- PEX2, PEX3, PEX10, PEX12, PEX16: Import machinery components
Known pathogenic variants:
- Missense mutations: R761Q, L987F
- Nonsense mutations: W234X, R653X
- Frameshift mutations
- Splice site variants
- Severe mutations: Zellweger syndrome
- Missense mutations: milder phenotype
- Compound heterozygosity common
- Panel testing for peroxisome biogenesis disorders
- Whole exome sequencing
- Carrier testing for at-risk families
AAV-mediated PEX6 delivery:
- Preclinical models show promise
- Targeted to brain via crossing BBB
- Restoration of peroxisomal function
- Combination with metabolic co-factors
Drug candidates:
- Farnesoid X receptor (FXR) agonists increase PEX expression
- PPAR agonists enhance peroxisomal function
- Antioxidants address oxidative stress
- VLCFA-lowering agents
Supportive therapies:
- Very long-chain fatty acid restriction
- Plasmalogen supplementation
- Antioxidant supplementation
- DHA and EPA supplementation
- Patient-derived fibroblasts
- PEX6 knockout cell lines
- iPSC-derived neurons
- Organoid models
- PEX6 knockout mice
- Zebrafish models
- Drosophila melanogaster
- Conditional knockout systems
PEX6 is essential for peroxisome biogenesis and function. Mutations cause severe peroxisome biogenesis disorders with neurological involvement. Emerging evidence links PEX6 dysfunction to common neurodegenerative diseases including Alzheimer's and Parkinson's disease. Understanding PEX6 biology provides insights into peroxisomal contributions to neurodegeneration and potential therapeutic strategies.
- Steinberg D, et al. PEX6 in peroxisome biogenesis. Hum Mol Genet. 2004;13(18):2051-2057. DOI
- Francisco T, et al. Peroxisome biogenesis: The peroxisomal importomer. Cell Mol Life Sci. 2017;74(9):1567-1582. DOI
- Steinberg S, et al. Peroxisome biogenesis disorders: phenotypic spectrum, pathophysiology and therapeutic approaches. Orphanet J Rare Dis. 2015;10:7. DOI
- Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta. 2012;1822(9):1430-1441. DOI
Page updated: 2026-03-05